A reliable and sensitive liquid chromatography-tandem mass spectrometry assay has been proposed for the selective determination of diflunisal in the presence of its glucuronide metabolites. The analyte and clofibric acid as internal standard (IS) are extracted from 50 mL of human plasma by solid-phase extraction. Chromatographic separation is conducted on a Prodigy ODS 3V column (150 3 4.6 mm, 5 mm) under isocratic conditions. The possible interference of acyl glucuronide and phenolic glucuronide, the two major inactive metabolites of diflunisal, is also checked in plasma samples. Detection of the analyte and IS is achieved by tandem mass spectrometry, operating in negative ionization and multiple reaction monitoring acquisition mode. The limits of detection and quantitation of the method are 0.10 and 1.00 mg/mL, respectively, with a linear dynamic range of 1.00 -160 mg/mL for diflunisal. The intra-batch and inter-batch precision ( percent coefficient of variation) is 4.2% and the mean recovery is >92% for diflunisal across quality control levels. The method is successfully applied to a bioequivalence study of a 500 mg diflunisal tablet formulation in 30 healthy Indian male subjects under fasting conditions. The reproducibility in the measurement of study data is demonstrated by the reanalysis of 120 incurred samples.
Introduction
Diflunisal [DFL (2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid)], a difluorophenyl derivative of salicylic acid, belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs) with analgesic, anti-inflammatory and antipyretic properties (1, 2) . DFL is a peripherally acting analgesic agent with a long duration of action. It is rapidly and completely absorbed following oral administration with peak plasma concentrations occurring between 2 and 3 h (3). More than 99% of DFL in plasma is bound to proteins. DFL is almost entirely eliminated from the body by biotransformation to three metabolites; namely, acyl glucuronide, the phenolic glucuronide and the sulphate conjugates. They are excreted in the urine and account for approximately 90% of the administered dose in healthy volunteers (3 -6) .
Several analytical methods have been reported to determine DFL in biological matrices, either alone (7 -11) or together with its glucuronide metabolites (12) . The majority of the methods are based on high-performance liquid chromatographic (HPLC) determination of DFL in human plasma (7) (8) (9) (10) (11) , serum (9) and urine (8 -11) . In these methods, either the sensitivity (7, 8, 10) , analysis time (7 -10) or plasma volume for processing (7, 8) is the limiting factor. Moller et al. (12) have developed a reversed-phase HPLC assay for the simultaneous determination of DFL and its glucuronide metabolites in serum and urine. The analysis of the urinary metabolites, ether and ester glucuronide have been studied in human urine and serum by HPLC (13, 14) . Furthermore, DFL has also been determined along with other NSAIDs by gas chromatography-mass spectrometry (GC-MS) (15) , fluorescence spectroscopy (16, 17) and HPLC with ultraviolet (18) or amperometric detection (19) . To date, there have been no reports on the use of liquid chromatography (LC) with mass spectrometry (MS) detection for the quantitation of DLF in human plasma. In the present study, a sensitive, selective, rugged and rapid LC -MS method was proposed for the determination of DFL in human plasma. The method was extensively validated as per the guidelines of the United States Food and Drug Administration (USFDA) and is adequately sensitive for routine subject sample analysis. The method requires only 50 mL of human plasma for solid-phase extraction (SPE) and demonstrates excellent performance in terms of ruggedness and efficiency (5.0 min per sample). The dynamic linear range was validated from 1.0 -160 mg/mL. The method is selective in the presence of its glucuronide metabolites, four NSAIDs; namely, ibuprofen, naproxen, diclofenac and aspirin, and some commonly used medications by human volunteers. Ion suppression and enhancement were studied by post-column infusion of the analyte and a post-extraction spiking technique. The proposed method was successfully applied to a bioequivalence study of a 500 mg DFL orally disintegrating tablet formulation in 30 healthy Indian males under fasting conditions. The reliability in the measurement of study samples was shown by incurred sample reanalysis.
Experimental

Chemicals and materials
Reference standard materials of DFL (99.3%) and clofibric acid [internal standard (IS), 99.0%] were procured from Zydus Cadila (Ahmedabad, India) and Vivan Life Sciences (Mumbai, India), respectively. Diflunisal phenolic glucuronide lithium salt (DPG, 99.7%) and diflunisal acyl glucuronide (DAG, 96.0%) were obtained from TLC Pharmachem (Vaughan, Ontario, Canada). HPLC-grade methanol and acetonitrile, analyticalgrade reagent formic acid (98.0%), ammonium formate (99.5%), sodium hydroxide pellets (.99.0%) and ammonia solution (30.0%) were purchased from S.D. Fine Chemicals(Mumbai, India). Oasis HLB (1 cc, 30 mg) extraction cartridges were obtained from Waters Corporation (Milford, MA).
Water used for LC-MS was prepared using a Milli-Q water purification system from Millipore (Bangalore, India). Control buffered (K 2 EDTA) human plasma was procured from the Clinical Department of BA Research India (Ahmedabad, India) and was stored at -208C. The elution solution consisted of acetonitrile -5mM ammonium formate, pH 8.0 adjusted with ammonia solution (90:10, v/v).
LC -MS instrumentation and settings
The liquid chromatography system from Shimadzu (Kyoto, Japan) consisted of an LC-10ADvp pump, an autosampler (SIL-HTc) and an online degasser (DGU-14A). The chromatographic column was a Phenomenex Prodigy ODS 3V (150 mm length Â 4.6 mm inner diameter, with 5.0 mm particle size) from Phenomenex (Torrance, CA). The mobile phase consisted of acetonitrile -5 mM ammonium formate (45:55, v/v) and was delivered at a flow rate of 0.60 mL/min under isocratic conditions. The autosampler temperature was maintained at 48C. Ionization and detection of the analyte and IS were performed on a triple quadrupole MS, API-3000, equipped with Turbo Ion Spray from MDS SCIEX (Toronto, Canada) operating in the negative ionization mode. Quantitation was done using multiple reaction monitoring (MRM) mode to monitor the deprotonated precursor ! product ion transitions of m/z 249.0 ! 205.0 for DFL and m/z 213.1 ! 126.9 for IS. All LC and MS parameters were controlled by Analyst software, version 1.4.2. The spectral processing criteria included Gaussian smoothing options with Gaussian filter width (100% by default), and limit of Gaussian filter (number of minimal distance between points) of 10. Baseline subtraction was based on the next point weight of 4 amu or 2 min, threshold values were set at 5.0e 6 and 5.0e 4 cps for DLF and 1.0e 7 and 1.0e 6 cps for IS in Q1 and Q3 mass spectra, respectively.
For DFL and IS, the source-dependent parameters maintained were gas 1 (nebulizer gas): 14 psi, ion spray voltage (ISV): -3,000 V, turbo heater temperature (TEM): 4008C, entrance potential (EP): -10 V, collision activation dissociation (CAD): 4 psi, curtain gas (CUR): 14 psi. The compound-dependent parameters like declustering potential (DP), focusing potential (FP), collision energy (CE) and cell exit potential (CXP) were optimized at -65, -120, -32 and -12 V for DFL and -30, -80, -24 and -14 V for IS, respectively. Quadrupoles 1 and 3 were maintained at unit resolution, and the dwell time was set at 300 ms for DFL and IS.
Preparation of standard stock and plasma samples A DFL standard stock solution of 10.0 mg/mL was prepared by dissolving the requisite amount in methanol-50 mM sodium hydroxide (90:10, v/v) solution. This was further diluted in the same diluent to produce an intermediate solution of 3,200 mg/ mL. The working solutions of DFL for spiking plasma calibration and quality control samples were subsequently prepared using the standard and intermediate stock solutions. Both DPG and DAG standard stock solutions of 10.0 mg/mL were prepared by dissolving the requisite amounts in acetonitriledeionized water (85:15, v/v) and acetonitrile, respectively.
They were further diluted in the same diluents to produce intermediate solutions of 3,200 mg/mL. The IS stock solution of 1,000 mg/mL was prepared by dissolving the requisite amount of clofibric acid in methanol. The IS working solution (50.0 mg/mL) was prepared using the stock solution in deionized water. All of these solutions were stored at 48C until use. The calibration standards (CS) and quality control (QC) samples [lower limit of quantitation (LLOQ) QC at 1.00 mg/mL, low quality control (LQC) at 3.00 mg/mL, two medium quality controls (MQC-2 and MQC-1) at 19.0 and 80.0 mg/mL, respectively; high quality control (HQC) at 120 mg/mL, upper limit of quantitation (ULOQ) QC at 160 mg/mL] were prepared by spiking blank plasma with respective working solutions (5% of total volume of plasma). CSs were made at 1.00, 2.00, 5.00, 10.0, 15.0, 30.0, 60.0, 100, 130 and 160 mg/mL for DFL. The spiked plasma samples at all levels were acidified with formic acid (2% of sample volume) and stored at -708C for validation and subject sample analysis.
Protocol for sample preparation Before analysis, spiked plasma samples were thawed in a wet ice bath and allowed to equilibrate at room temperature. The samples were adequately vortexed using a vortexer before pipetting. Aliquots of 50 mL plasma solution containing 2.5 mL of the working solution of DFL and 47.5 mL of blank plasma were transferred into ria vials, and 200 mL of working solution of IS (50.0 mg/mL) was added and vortexed. To the same ria vials, 750 mL of 2% formic acid solution was added and vortexed again. All of these steps were performed in a wet ice bath. Before loading plasma samples, Oasis HLB SPE cartridges were pre-washed with 1.0 mL of methanol followed by 1.0 mL of deionized water, and centrifuged after each step for 1.0 min at 1,811 Â g at 48C. Plasma samples were then applied to these conditioned cartridges, and after centrifugation at 1,811 Â g for 2.0 min at 48C, washing was conducted with 1.0 mL of deionized water, followed by centrifugation for 1.0 min at 1,811 Â g at 48C. The elution of samples was conducted with 1.0 mL of elution solution, followed by centrifugation for 1.0 min at 1,811 Â g at 48C. Furthermore, 100 mL of eluate was added to ria vials, and 800 mL of elution solution was added and briefly vortexed. From this solution, 5.0 mL was used for injection into the LC-MS, in partial loop mode.
Validation methodology
A thorough and complete method validation of DFL in human plasma was conducted following USFDA guidelines (20) . The method was validated for cross validation, selectivity, cross specificity, sensitivity, limit of detection, interference, carryover, linearity, precision and accuracy, reinjection reproducibility, recovery, ion suppression/enhancement, matrix effect, stability and dilution integrity. To check the potential interference of glucuronide metabolites during sample storage, sample extraction and chromatography, DFL QC samples were fortified with DAG and DPG. In assay cross validation, one set of CSs, six sets of QCs (HQC, MQC-1, MQC-2 and LQC), two sets of extracted blank plasma samples (with IS), two sets of double blank plasma samples (without IS) and six sets of QCs (HQC, MQC-1, MQC-2 and LQC) fortified with glucuronides (160 mg/mL) were injected.
The test for selectivity was conducted in 12 different lots of blank human plasma including hemolyzed and lipemic plasma collected with K 2 EDTA as an anticoagulant. From each of these 12 different lots, two replicates of 47.5 mL each were spiked with 2.5 mL of methanol-50 mM sodium hydroxide (90:10, v/v) solution. In the first set, the double blank plasma (without analyte and IS) was directly injected after extraction, and the other set was only spiked with IS before extraction (total of 24 samples). Furthermore, one system suitability sample (SSS) at CS-2 (2.00 mg/mL) concentration and two replicates of LLOQ concentration (CS-1) were prepared by spiking 47.5 mL of blank human plasma with 2.5 mL of working aqueous standards of DFL. The acceptance criterion requires that at least 90% of selectivity samples should be free from any interference at the retention times of the analyte and IS. For the cross specificity experiment, one SSS, two replicates of LLOQ concentrations, one extracted blank plasma (with IS), one double blank plasma (without IS), one blank plasma spiked with DAG (160.0 mg/mL) and one blank plasma spiked with DPG (160.0 mg/mL) were injected.
The interference due to commonly used medications in human volunteers was examined for acetaminophen, caffeine, cetrizine, chlorpheniramine maleate and pseudoephedrine. Additionally, four NSAIDs; namely, ibuprofen, naproxen, diclofenac and aspirin, were studied for ionization (ion suppression/ enhancement), analytical recovery ( precision and accuracy) and chromatographic interference (interference with MRM of the analyte and IS). Their stock solutions (100 mg/mL) were prepared by dissolving the requisite amounts in methanol. Furthermore, working solutions (20.0 mg/mL) were prepared in methanol-50 mM sodium hydroxide (90:10, v/v) solution, spiked in plasma and analyzed under the same conditions at LQC and HQC levels in triplicate. These sets were processed along with freshly prepared CSs and two sets (eight samples) of qualifying QC samples (HQC, MQC-1, MQC-2 and LQC). As per the acceptance criteria, the percent accuracy should be within 85 to 115%. The MRM transitions in the negative ionization mode for ibuprofen (205/161), naproxen (229/185), diclofenac (294/250) and aspirin (179/137) were studied.
A carryover experiment was performed to verify any carryover of the analyte, which may reflect in subsequent runs. The design of the study was composed of the following sequence of injections; i.e., double blank plasma sample to two samples of LLOQ to double blank plasma to ULOQ sample to double blank plasma, to check for any interference due to carryover. The linearity of the method was determined by the analysis of eight calibration curves containing 10 non-zero concentrations. The area ratio response for DFL/IS obtained from MRM was used for regression analysis. Each calibration curve was individually analyzed by using least-square weighted (1/x 2 ) linear regression. The lowest standard on the calibration curve was accepted as the LLOQ, if the analyte response was at least 10 times more than that of drug-free (blank) extracted plasma.
Intra-batch and inter-batch (on three consecutive validation days) accuracy and precision were evaluated at six QC levels (LLOQ QC, LQC, MQC-2, MQC-1, HQC and ULOQ QC) in six replicates for DFL. The deviation [ percent coefficient of variation (CV)] at each concentration level from the nominal concentration was expected to be within +15%. Similarly, the mean accuracy should not vary by +15%, except for the LLOQ, where it can be +20% of the nominal concentration. Also, two out of three QC samples should meet the criteria of +15% of the nominal concentration. Precision (CV) values for reinjection reproducibility were checked by re-injecting one entire validation batch.
The relative recovery, matrix effect and process efficiency were evaluated as recommended by Matuszewski et al. (21) at HQC, MQC-1, MQC-2 and LQC levels in six replicates. Relative recovery (RR) was calculated by comparing the mean area response of samples spiked before extraction to that of samples spiked after extraction at each QC level. The recovery of the IS was similarly estimated. Absolute matrix effect (ME) was assessed by comparing the mean area response of samples spiked after extraction with the mean area response of neat standard solutions prepared in the mobile phase. The overall process efficiency (PE) was calculated as (ME Â RR) / 100. The relative ME on analyte quantification was also checked in six different batches/lots of K 2 EDTA plasma, including hemolyzed and lipemic plasma. From each batch, four samples at LQC and HQC levels was prepared (spiked after extraction) and checked for the percentage of accuracy and precision (CV). The deviation of the standards and QCs should not be more than +15%.
Matrix ion suppression effects on the MRM LC-MS sensitivity were evaluated by the post-column analyte infusion experiment (22) . A standard solution containing 80.0 mg/mL of DFL and 50.0 mg/mL of IS in mobile phase was infused post column via a T-connector into the mobile phase at 5.0 mL/min, employing a Harvard infusion pump. Aliquots of 5.0 mL of the extracted 160.0 mg/mL sample and double blank plasma sample were then injected and MRM LC-MS chromatograms were acquired for DFL and IS. Any dip in the baseline upon injection of the double blank plasma would indicate ion suppression, whereas peaks at the retention times of DFL and IS indicates ion enhancement.
All stability results were evaluated by measuring the area ratio response (DFL/IS) of stability samples against freshly prepared comparison standards at LQC and HQC levels in the presence of DAG and DPG. Stock solutions of DFL and IS were checked for short-term stability at room temperature and longterm stability at 48C. The solutions were considered to be stable if the deviation from nominal value was within +10.0%. Bench-top stability, processed sample stability at room temperature and refrigerated temperature (48C), freeze -thaw stability and long-term stability at -708C were performed at LQC and HQC levels using six replicates at each level. To meet the acceptance criteria, the CV and accuracy should be within +15%. Also, at least two-thirds of the QC samples should meet the criteria of +15% of the nominal concentration.
A dilution integrity experiment was conducted by diluting the stock solution that was prepared as a spiked standard at five times the ULOQ concentration; i.e., 800 mg/mL, and at the level of HQC for DFL in the screened plasma. Six replicate samples each of 1/10 of 5 Â ULOQ (80.0 mg/mL) and 1/10 of HQC (12.0 mg/mL) concentrations were prepared and their concentrations were calculated by applying the dilution factor of 10 against the freshly prepared calibration curve for DFL.
Bioequivalence study and incurred sample reanalysis The study plan was defined as "An open label, randomized, twoperiod, two-treatment, two-sequence, balanced, crossover, single dose evaluation of relative oral bioavailability of test (500 mg diflunisal tablets of a generic company) and a reference (500 mg diflunisal tablets from Teva Pharmaceutical USA, Sellersville, PA) formulation in 30 healthy Indian subjects under fasting conditions." All subjects were informed of the aim and risk involved in the study and written consents were obtained. The inclusion criteria for volunteer selection was based on the age (18 years or above), body mass index (between 18.5 and 24.9 kg/height 2 ), general physical examination, electrocardiogram, and laboratory tests like hematology, blood chemistry, urine examination and immunological tests. The exclusion criteria included allergic responses to DFL, volunteers with a history of alcoholism or smoking, and volunteers with diabetes, psychosis, or a disease that may compromise the hemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system. The work was approved and subject to review by the Institutional Ethics Committee, an independent body composed of eight members that includes a lawyer, medical doctors, social workers, pharmacologists and academicians. The procedures followed while dealing with human subjects were based on the International Conference on Harmonization, E6 Good Clinical Practice (ICH, E6 GCP) guidelines (23) . The subjects for study were fasted for 10 h before administration of the drug formulation. Blood samples were collected in vacutainers containing K 2 EDTA anticoagulant before (0.0 h) and at 0. ). An incurred sample re-analysis (ISR) was also conducted by computerized random selection of 120 subject samples (10% of total study samples analyzed) near the maximum plasma concentration (C max ) and the elimination phase. The results were compared with the data obtained earlier for the same sample using the same procedure. The percent change in the value should not be more than +20% (24).
Results and Discussion
Method development
The method development was initiated to realize a rugged, rapid and selective LC-electrospray ionization (ESI)-MS method to quantify DFL in human plasma in the presence of ester and ether glucuronide metabolites. To achieve this aim, it was essential to have an efficient extraction procedure and acceptable chromatographic separation in a short run time. Also, the sensitivity needed to be adequate enough to monitor at least five half-lives of DFL concentration with good accuracy and precision for the subject samples. The tuning of MS parameters was conducted in negative ionization mode for DFL and IS, because both drugs have a carboxylic acid group. The analyte and IS gave predominant singly charged deprotonated precursor [M-H] 2 ions at m/z of 249.0 and 213.1 for DFL and IS, respectively, in Q1 full scan spectra. In the product ion mass spectrum of DFL, the most abundant and consistent ion was observed at m/z 205.0, which can be attributed to the loss of CO 2 from the precursor ion ( Figure 1A ). The major product ion for clofibric acid (IS) in Q3 mass spectra was found at m/z 126.9 by applying CE of -24.0 eV ( Figure 1B ). This fragment was produced by O-C bond cleavage to give a 4-chloro phenoxy substructure. To attain an ideal Taylor cone and a better impact on the spectral response, an optimum potential of 3,000 V was kept, which gave a consistent and stable signal. Fine-tuning of the nebulizer gas (14.0 psi) and CAD gas was conducted to produce consistent and stable responses. The ion source chamber temperature had little effect on the signal, and hence, was maintained at 4008C. A dwell time of 300 ms was adequate and no cross talk was observed between the MRMs of the analytes.
The chromatographic conditions were initiated to achieve efficient separation and resolution from the glucuronide metabolites under isocratic conditions. This included mobile phase selection, flow rate and injection volume. Based on this approach, these parameters were suitably optimized to achieve a short run time, symmetric peak shapes, minimum matrix interference and solvent consumption. Different volume ratios (75:25, 65:35, 55:45 and 45:55, v/v) of methanol-water and acetonitrile -water combinations were tried as the mobile phase, along with formic acid (0.01-0.005%) and ammonium formate (2 -20 mM) on a Phenomenex Prodigy column (150 Â 4.6 mm, 5 m) with pore size of 100 Å , carbon loading 15% and high surface area of 450 m 2 /g. In addition, the effect of flow rate was also studied from 0.3 to 1.0 mL/min, which was also responsible for acceptable chromatographic peak shapes. Efficient separation with adequate retention was possible using a mobile phase consisting of acetonitrile-5 mM ammonium formate (45:55, v/v). A flow rate of 0.6 mL/min was found to be most suitable for acceptable peak shapes and run time. For volume ratios with organic modifier greater than 45%, the retention was inadequate with poor chromatography. The retention times observed for DFL, DAG, DPG and IS were 3.38, 2.29, 1.87 and 2.39 min, respectively. Baseline separation of both metabolites and DFL was possible within 5.0 min, as shown in Figures 2A and 2B at HQC and LQC levels. The resolution factors between DFL and DAG/DPG were 1.8/3.0. The reproducibility of retention times for the analyte, expressed as CV, was 0.8% for 100 injections on the same column. Ideally, a deuterated analogue should be the first-choice internal standard, but due to its unavailability, a general IS was used to minimize analytical variation due to solvent evaporation and ionization efficiency. Clofibric acid, used as an IS in the present study, had similar chromatographic behavior and was easily eluted with the analyte. There was no effect of IS on analyte recovery, sensitivity or ion suppression.
Previous reports have used either liquid -liquid extraction (LLE) (7, 9) or protein precipitation (PP) (8, 11) for the quantitative extraction of DFL from human plasma. PP was initially tried (due to high protein binding of the drug) using methanol, ethanol and acetonitrile as precipitating agents, but the response was inconsistent, with some ion suppression. Thus, LLE was conducted in solvent systems reported in existing methods (7, 9) like diethyl ether, n-hexane and their combinations. However, the response was inadequate, especially at the LLOQ level. Finally, SPE was tried on Oasis HLB cartridges using 2% (v/v) formic acid solution to break the drug protein binding. Consistent and quantitative recovery (!90%) was obtained for DFL and IS at all QCs levels employing 50 mL plasma volume for processing.
System suitability, selectivity, interference and carryover check During method validation, the precision (CV) of the system suitability test was observed in the range of 0.11 to 0.54% for the retention time and 1.4 to 2.0% for the area responses of DFL and IS. The cross-validation and specificity results indicated practically no interference from the glucuronide metabolites. Because both metabolites were baseline separated from the analyte, there was no interference during quantitation of DFL. Consequently, the MRM study of the metabolites was not required in the present work. All plasma samples studied for the selectivity check were found to be free from any endogenous interference. Figures 3A-C demonstrate the selectivity results with the chromatograms of double blank plasma (without IS), blank plasma (with IS) and peak response of DFL at LLOQ concentration. No interference was observed for commonly used medications like acetaminophen, caffeine, cetrizine, chlorpheniramine and pseudoephedrine, which is evident from the real subject sample chromatograms of DFL at 2.75 h after oral administration of a 500 mg tablet formulation ( Figure 3D) . None of the NSAIDs interfered in the determination of DFL. Under the optimized experimental conditions, the retention times for ibuprofen, naproxen, diclofenac and aspirin were observed at 3.55, 3.67, 3.86 and 2.13 min, respectively. However, due to the different MRM transitions, there was no interference in the quantification of DFL. The percent accuracy results for DFL at both QC levels were within 95.5 to 103.6%. An evaluation of carryover was performed to ensure that it did not affect the accuracy and precision of the proposed method. An almost negligible area (less than 0.5% of the LLOQ area) was observed in the double blank plasma run after ULOQ, which suggests no carryover of the analyte in subsequent runs.
Linearity, sensitivity, accuracy and precision All eight calibration curves were linear over the concentration range of 1.00 -160.0 mg/mL with correlation coefficient r ! 0.9983. A straight-line fit was made through the data points by least-square regression analysis to give the mean linear equation y ¼ (0.0036 + 0.0004)x þ (0.0003 + 0.0001), where y is the peak area ratio of the analyte/IS and x is the concentration of the analyte. The accuracy and precision (CV) observed for the calibration curve standards ranged from 92.1 to 105.0% and 1.4 to 4.7%, respectively. The lowest concentration (LLOQ) in the standard curve that can be measured with acceptable accuracy and precision was 1.00 mg/mL at a signal-to-noise ratio (S/N) ! 17. The limit of detection (LOD) of the method was 0.10 mg/mL.
The intra-batch precision (CV) ranged from 1.2 to 3.7 and the accuracy was within 93.4 to 104.1%. For the inter-batch experiments, the precision varied from 2.1 to 4.2 and the accuracy was within 94.0 to 105.1%. The detailed results at different QC levels are shown in Table I .
Recovery, ME, matrix factor, ion suppression The relative recovery of the analyte is the true recovery, which is unaffected by the matrix because it is calculated by comparing the area ratio response (analyte/IS) of extracted (spiked before extraction) and unextracted (spiked after extraction) samples. The relative recovery obtained for DFL and IS was .90 % at all QC levels (Table II) . Furthermore, the relative ME, which compares the precision (CV) values between different lots (sources) of plasma (spiked after extraction) samples varied from 0.6 to 3.7 for DFL at the LQC and HQC levels. The results of the post-column analyte infusion experiment in Figure 4 indicate no ion suppression or enhancement at the retention times of DFL and IS. A minor enhancement in the response was observed at approximately 2.1 min; however, it did not interfere in the quantitation. The average matrix factor value calculated as the response of post-spiked sample/response of neat solution (in mobile phase) at the LLOQ level was 1.01, which indicates a minor enhancement of approximately 1%.
Stability and dilution integrity
The stock solution of DFL was stable at room temperature for 6 h and at 48C for 30 days. The intermediate stock solutions of DFL in methanol-50 mM sodium hydroxide (90:10, v/v) were stable at 48C for nine days with a percentage change of -0.6. DFL was found to be stable in controlled plasma in a wet ice bath at room temperature up to 24 h and for six freeze and thaw cycles in a wet ice bath. The analytes in extracted plasma samples were stable for 72 h under refrigerated conditions (48C) and for 16 h at room temperature. The spiked plasma samples of DFL stored at -708C for long-term stability were found to be stable for minimum period of 93 days. The values of percent change for all stability experiments are compiled in Table III. The precision values for dilution integrity of 1/10 of 5 Â ULOQ (80.0 mg/mL) and 1/10 of HQC (12.0 mg/mL) concentrations were 0.8 and 1.3%, and the accuracy results were within 104.5 and 95.1, respectively, which is within the acceptance limit of 15% for precision (CV) and 85 to 115% for accuracy. Application of the method in human subjects and incurred sample reanalysis The mean pharmacokinetic profile for the treatment under fasting conditions is presented in Figure 5 . Approximately 2,087 samples, including the calibration, QC and volunteer samples, were successfully run and analyzed. The precision and accuracy for calibration and QC samples were well within the acceptable limits. The mean pharmacokinetic parameters obtained for the test and reference formulations for both studies are presented in Table IV . DFL has a linear pharmacokinetic profile over a dose range of 50 to 1,000 mg (25) . The C max , time point of the maximum plasma concentration (T max ) and half-life of the drug elimination during the terminal phase (t 1/2 ) values obtained in the present work are comparable with a previous work using 500 mg drug formulation (26) . The equivalence statistics of bioavailability for the pharmacokinetic parameters of the two formulations are summarized in Table V . The mean log-transformed ratios of the parameters and their 90% CIs were all within the defined bioequivalence range. These observations confirm the bioequivalence of the Figure 5 . Mean plasma concentration-time profile of DFL after oral administration of test (500 mg DFL tablets from a generic company) and a reference (500 mg DFL tablets from Teva Pharmaceutical USA, Sellersville, PA) formulation to 30 healthy Indian subjects under fasting conditions. test sample with the reference product in terms of rate and extent of absorption. The percent change in the randomly selected subject samples for incurred sample reanalysis was within 13.6 to -8.8%. This authenticates the reproducibility of the proposed method.
Comparison with reported methods
The proposed method has superior sensitivity compared to the majority of the methods (7, 8, 10, 18) developed in plasma, and employs a minimum plasma volume (50 mL) for processing. Moreover, the total analysis time (extraction and chromatography) is the shortest compared to all of these methods, except one report (10) . Also, the on-column loading of DFL at ULOQ was 3.5 ng per sample injection volume. This is considerably less than all other reported procedures, which helps to maintain the efficiency and the lifetime of the column. Incurred sample reanalysis, which has now become mandatory for clinical and non-clinical studies, was demonstrated to prove the reproducibility of the proposed method in healthy subject samples. A detailed comparison of the highlights of the present method with reported chromatographic procedures for DFL in plasma is shown in Table VI .
Conclusion
Currently, there are no reports for the estimation of DFL in human plasma by LC-MS. The objective of this work was to develop a selective, sensitive, rugged and high-throughput LC-MS method for routine analysis. The SPE procedure employed in the present work gave consistent and quantitative recoveries for DFL at all QC levels. Chromatographic separation of both the glucuronide metabolites and DFL was possible within 5.0 min. Moreover, the limit of quantification is low enough to monitor at least five half-lives of DFL concentration with good intra-assay and inter-assay reproducibility (CV) for the quality controls. The method was selective in presence of four NSAIDs and some commonly used medications by human volunteers. The sensitivity of the proposed method is adequate to support a wide range of pharmacokinetic and bioequivalence studies. 
